These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
112 related articles for article (PubMed ID: 9499670)
21. Ischemic colitis and acquired resistance to activated protein C in a woman using oral contraceptives. Mann DE; Kessel ER; Mullins DL; Lottenberg R Am J Gastroenterol; 1998 Oct; 93(10):1960-2. PubMed ID: 9772065 [TBL] [Abstract][Full Text] [Related]
22. Resistance to activated protein C and low levels of free protein S in Greek patients with inflammatory bowel disease. Koutroubakis IE; Sfiridaki A; Mouzas IA; Maladaki A; Kapsoritakis A; Roussomoustakaki M; Kouroumalis EA; Manousos ON Am J Gastroenterol; 2000 Jan; 95(1):190-4. PubMed ID: 10638581 [TBL] [Abstract][Full Text] [Related]
23. Factor V Leiden mutation in one family of Chinese origin. Wu J; Gu J; Xu J; Wang J; Sun Z; Smirnov MD; Morrissey JH; Esmon N Chin Med J (Engl); 2001 Apr; 114(4):379-81. PubMed ID: 11780458 [TBL] [Abstract][Full Text] [Related]
24. Factor V Leiden, prothrombin 20210G-->A and the MTHFR C677T mutations in childhood stroke. McColl MD; Chalmers EA; Thomas A; Sproul A; Healey C; Rafferty I; McWilliam R; Eunson P Thromb Haemost; 1999 May; 81(5):690-4. PubMed ID: 10365738 [TBL] [Abstract][Full Text] [Related]
25. [Diagnosis of thrombophilia based on coagulation and genetic studies]. Bałszan-Kowalska I Ann Acad Med Stetin; 2002; 48():179-93. PubMed ID: 14601477 [TBL] [Abstract][Full Text] [Related]
26. Primary thrombophilia in Mexico IV: frequency of the Leiden, Cambridge, Hong Kong, Liverpool and HR2 haplotype polymorphisms in the factor V gene of a group of thrombophilic Mexican Mestizo patients. Ruiz-Argüelles GJ; Poblete-Naredo I; Reyes-Núñez V; Garcés-Eisele J; López-Martínez B; Gómez-Rangel JD Rev Invest Clin; 2004; 56(5):600-4. PubMed ID: 15776863 [TBL] [Abstract][Full Text] [Related]
27. Clinical evaluation of a new functional test for detection of activated protein C resistance (Pefakit APC-R Factor V Leiden) at two centers in Europe and the USA. Schöni R; Quehenberger P; Wu JR; Wilmer M Thromb Res; 2007; 119(1):17-26. PubMed ID: 16934314 [TBL] [Abstract][Full Text] [Related]
28. Factor V Leiden mutation, deficiency of antithrombin III and elevation of factor VIII in a child with ischemic stroke: a case report. Duran R; Biner B; Demir M; Celtik C; Karasalihoğlu S; Acunaş B Brain Dev; 2006 Oct; 28(9):604-6. PubMed ID: 16644163 [TBL] [Abstract][Full Text] [Related]
29. Evaluation of smoking as a risk factor for activated protein C resistance during pregnancy. Kafkas S; Kalkan U; Bolaman Z; Sanci M; Yüksel H; Odabaşi AR Gynecol Obstet Invest; 2007; 64(2):89-94. PubMed ID: 17314487 [TBL] [Abstract][Full Text] [Related]
30. Anterior ischemic optic neuropathy and activated protein C resistance. A case report and review of the literature. Worrall BB; Moazami G; Odel JG; Behrens MM J Neuroophthalmol; 1997 Sep; 17(3):162-5. PubMed ID: 9304527 [TBL] [Abstract][Full Text] [Related]
31. [Activated protein C resistance and mutation of coagulation factor V]. Samama MM Arch Mal Coeur Vaiss; 1996 Jun; 89(6):669-70. PubMed ID: 8760650 [No Abstract] [Full Text] [Related]
32. Resistance to activated protein C: a common anticoagulant deficiency in patients with venous leg ulceration. Peus D; Pittelkow MR Br J Dermatol; 1997 Aug; 137(2):322-3. PubMed ID: 9292102 [No Abstract] [Full Text] [Related]
33. Reduced response to activated protein C is associated with increased risk for cerebrovascular disease. van der Bom JG; Bots ML; Haverkate F; Slagboom PE; Meijer P; de Jong PT; Hofman A; Grobbee DE; Kluft C Ann Intern Med; 1996 Aug; 125(4):265-9. PubMed ID: 8678388 [TBL] [Abstract][Full Text] [Related]
34. [Screening in activated protein C resistance]. Bergmann F Internist (Berl); 1997 Sep; 38(9):864. PubMed ID: 9410836 [No Abstract] [Full Text] [Related]
35. Resistance to activated protein C in thalassaemic patients: an underlying cause of thrombosis. Giordano P; Del Vecchio GC; Altomare M; Coppola B; Schettini F; Iolascon A; De Mattia D Eur J Haematol; 1998 Aug; 61(2):123-7. PubMed ID: 9714525 [TBL] [Abstract][Full Text] [Related]
36. Factor V R506Q gene mutation analysis by PCR-RFLP: optimization, comparison with functional testing for resistance to activated protein C, and establishment of cell line controls. Voelkerding KV; Wu L; Williams EC; Hoffman SM; Sabatini LM; Borcherding WR; Huber S Am J Clin Pathol; 1996 Jul; 106(1):100-6. PubMed ID: 8701917 [TBL] [Abstract][Full Text] [Related]
37. Primary antiphospholipid syndrome is not associated with activated protein C resistance caused by factor V Arg 506 -->Gln mutation. Biousse V; Piette JC; Frances C; Bletry O; Papo T; Tournier-Lasserve E; Duchemin J; Aiach M J Rheumatol; 1995 Jun; 22(6):1215. PubMed ID: 7674266 [No Abstract] [Full Text] [Related]
38. Activated protein C resistance due to a factor V mutation associated with familial ischemic stroke. De Lucia D; Nina P; Papa ML; Belli A; Conte M; Renis V; Di Mauro C; Masi S; Franco A; Schisano G J Neurosurg Sci; 1997 Dec; 41(4):373-8. PubMed ID: 9555645 [TBL] [Abstract][Full Text] [Related]
39. Resistance to activated protein C and ischemic arterial disease in a young man. Menezes IA; Romani RF; Aoki YS; Abdo JC; Carvalho M Arq Bras Cardiol; 2010 Mar; 94(3):e31-3, e91-3. PubMed ID: 20730250 [TBL] [Abstract][Full Text] [Related]
40. [Pulmonary embolism disclosing activated protein C resistance]. Strecker A; Bernardi F; Wolschies E; Hendricx S; Jude B Rev Mal Respir; 1996 Oct; 13(5):521-2. PubMed ID: 8999481 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]